Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor.
Dorzolamide is a powerful inhibitor of carbonic anhydrase (CA) II that penetrates the sclera and cornea to reach the ciliary process and lowers formation of HCO3 and aqueous humor. The usual dose applied to the eye in treatment of glaucoma is 1 drop (30 microL of 2% solution) every 8 hr to each eye, or a total daily dose of 4 mg. On this regime, the red cells accumulated drug over a period of 8 days, reaching a value of 20-25 microM, which corresponds to the concentration of CA II in human red cells. This drug concentration persisted throughout the 18 months of application. The plasma concentration was 0.034 microM, or 1/700 that of the red cells. This plasma concentration corresponds to that calculated from the dilution of administered drug into body water. The data are well fitted into the equilibrium expression for KI of dorzolamide against CA II at 37 degrees C, as 8 x 10(-9) M. The red cells also contain a small amount (5 microM) of the N-des-ethyl metabolite, probably reflecting its modest binding to CA I. In the initial 8-day drug period, virtually none appeared in the urine since CA II sites were being filled. At steady state, renal excretion was 1.3 mg/day and the renal clearance 90 ml/min. These excretion numbers include the small (20%) amount of the des-ethyl metabolite of dorzolamide. The relation of these data to lowering of intraocular pressure is clear. By the systemic route, an inhibitor such as acetazolamide is effective when free drug concentration in plasma is 2.5 microM. In the case of topical drugs, as shown here, the plasma concentration is some 100 x lower, but the concentration in ciliary process is 2-10 microM, comparable to that following systemic drugs (1). In conclusion, the concentration in plasma (reflecting free drug) of dorzolamide is about 1/200 of that needed for systemic effects as seen following acetazolamide or methazolamide. Thus, there is a clear pharmacological basis for the lack of any physiological effects of ocular dorzolamide, except on the eye itself.
Maren
T H
TH
Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, USA.
Conroy
C W
CW
Wynns
G C
GC
Levy
N S
NS
D000287:Administration, Topical; D000368:Aged; D002257:Carbonic Anhydrase Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005902:Glaucoma, Open-Angle / Q000097:blood / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000097:blood / Q000652:urine; D013449:Sulfonamides / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D013876:Thiophenes / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide